Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can emicizumab keep hemophilia joints healthy? new study aims to find out

NCT ID NCT07420348

Knowledge-focused Sponsor: Investigación en Hemofilia y Fisioterapia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow about 70 people with hemophilia A who are already taking emicizumab to prevent bleeding. Researchers will use ultrasound to check for early joint damage in elbows, knees, and ankles that are currently healthy. The goal is to see how often joint damage appears over two years and what factors might be linked to it. No new treatments or changes to care are involved.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with hemophilia A receiving prophylactic treatment with emicizumab

Ages

10 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of hemophilia A; * Receiving prophylactic treatment with emicizumab (Hemlibra®) according to routine clinical practice; * Age ≥10 years at the time of study enrollment; * Absence of ultrasonographic joint damage in at least one of the evaluated joints (elbows, knees, or ankles), defined as HEAD-US = 0 at baseline assessment; * No documented history of clinically evident hemarthrosis in the corresponding joints from initiation of emicizumab prophylaxis to the study baseline evaluation; * Ability to understand and complete study procedures (interviews, questionnaires, and clinical assessments), in accordance with the participant's age; and * Provision of written informed consent; for minors, written informed consent from parents or legal guardians and assent from the minor participant, in accordance with applicable regulations. Exclusion Criteria: * Presence of ultrasonographic joint damage (HEAD-US ≥1) in all evaluated joints at the baseline visit; * Documented history of clinically evident hemarthrosis in the joints under study; * Prior major orthopedic surgery or arthroplasty in the evaluated joints; * Presence of concomitant musculoskeletal pathology unrelated to hemophilia that could interfere with joint assessment (e.g., inflammatory arthritis, recent severe trauma); * Inability to complete the planned 24-month follow-up or to undergo study assessments; * Concurrent participation in another interventional study that could interfere with the joint health variables under evaluation; and * Any clinical or social condition that, in the investigator's judgment, could compromise participant safety or the validity of the study data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemophilia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemophilia hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemophilia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universidad de Oviedo

    Oviedo, Principality of Asturias, 33006, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.